Effects of a novel infant formula on weight gain and body composition 1 of infants: The INNOVA 2020 study 2

Julio Plaza-Diaz^{1,2,3,#}, Francisco Javier Ruiz-Ojeda^{1,2,4,5,#}, Javier Morales⁶, Ana Isabel Cristina 3 de la Torre⁷, Antonio García-García^{8,9}, Carlos Nuñez de Prado¹⁰, Cristóbal Coronel¹¹, Cyntia Crespo¹¹, Eduardo Ortega¹², Esther Marín-Pérez¹³, Fernando Ferrerira¹⁴, Gema García-Ron¹⁵, Ignacio Galicia⁸, María Teresa Santos-García-Cuéllar⁸, Marcos Moroto⁸, Paola Ruiz¹⁶, Raquel Martín¹⁷, Susana Viver-Gómez¹⁸ and Angel Gil^{1,2,5,19,*} 4 5

6

- 7
- ¹Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 8 9 18071, Granada, Spain
- ²Instituto de Investigación Biosanitaria IBS.GRANADA, Complejo Hospitalario Universitario de 10 Granada, Granada 18014, Spain 11
- 12 ³Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 8L1, Canada.
- ⁴RG Adipocytes and Metabolism, Institute for Diabetes and Obesity, Helmholtz Diabetes Center at 13 Helmholtz Center Munich, Neuherberg, 85764 Munich, Germany. 14
- ⁵Institute of Nutrition and Food Technology "José Mataix", Centre of Biomedical Research, 15 University of Granada, Avda, del Conocimiento s/n. 18016 Armilla, Granada, Spain 16
- 17 ⁶Product Development Department, Alter Farmacia SA, 28880 Madrid, Spain.
- ⁷CS Presentación sabio. C/Alonso Cano 8, 28933 Móstoles, Madrid 18
- ⁸Instituto Fundación Teófilo Hernando (IFTH). Parque científico de Madrid. UAM.. C/ Faraday 7. 19 Edificio CLAID. 28049. Madrid. 20
- ⁹Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, 21 22 Spain
- ¹⁰Consulta Privada Carlos Núñez, C/Santiago Apóstol 10, 28220 Majadahonda, Madrid, Spain 23
- ¹¹CS Amante Laffón. Pz San Martín de Porres 8, 41010, Sevilla. 24
- ¹²CAP Nova Lloreda, Av. De Catalunya 62-64, 08917 Badalona, Barcelona. 25
- ¹³CS Parque Loranca, C/ de la Alegría 2, 28942 Fuenlabrada, Madrid 26
- ¹⁴Consulta Externa Hospital Privado Santa Ángela de la Cruz, Av. De Jerez 59, 41013, Sevilla. 27
- ¹⁵CS La Rivota. C/ de las Palmeras s/n, 28922 Alcorcón, Madrid. 28
- 29 ¹⁶CS Las Américas, Av. De América 6, 28983 Parla, Madrid.
- ¹⁷CS Doctor Luengo Rodríguez, C/ Nueva York 16, 28938 Móstoles, Madrid. 30
- ¹⁸CS Valle de la Oliva. C/ Enrique Granados 2, 28222 Majadahonda, Madrid. 31

- ¹⁹CIBEROBN (CIBER Physiopathology of Obesity and Nutrition), Instituto de Salud Carlos III,
 28029 Madrid, Spain
- 34 [#]Equally contributed
- 35 *** Correspondence:**
- 36 Prof. Angel Gil

37 Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada,

- 38 Campus de Cartuja s/n, 18071, Granada, Spain
- 39 Phone: +34 695466922
- 40 agil@ugr.es
- 41 Abstract

42 Background: Breastmilk is the most appropriate food for infants and exclusive breastfeeding is 43 highly recommended for the first six months of life to promote adequate growth and development 44 and lower infant morbidity and mortality. Among the best-documented benefits of breastfeeding is 45 the reduced risk of disease and infections such as pneumonia, diarrhea and acute otitis media. 46 Nonetheless, there are situations in which the infant cannot be breastfed; therefore, it is essential to 47 use an appropriately designed infant formula. As current infant formulas incorporate novel 48 ingredients to partly mimic the composition of human milk, the safety and suitability of each specific 49 infant formula should be tested by clinical evaluation in the target population. Here, we report the 50 results of a multicenter, randomized, blinded, controlled clinical trial that aimed to evaluate a novel 51 starting formula on weight gain and body composition of infants up to 6 and 12 months (INNOVA 52 2020 study), as well as safety and tolerability. The complete protocol of this study has been 53 previously issued. Study design: 210 infants (70/group) were enrolled in the study, and completed 54 the intervention until 12 months of age. For the intervention period, infants were divided into three 55 groups: group 1 received the formula 1 (Nutribén® Innova1 or INN), with a lower amount of protein, and enriched in α -lactalbumin protein, and with a double amount of docosahexaenoic acid (DHA)/ 56 arachidonic acid (ARA) than the standard formula; it also contained a thermally inactivated 57 postbiotic (Bifidobacterium animalis subsp. lactis, BPL1TM HT). Group 2 received the standard 58 59 formula or formula 2 (Nutriben® Natal or STD) and the third group was exclusively breastfed for 60 exploratory analysis and used as a reference (BFD group). During the study, visits were made at 21 61 days, 2, 4, 6, and 12 months of age, with \pm 3 days for the visit at 21 days of age, \pm 1 week for the 62 visit at 2 months, and ± 2 weeks for the others. During the first 6 months of the study, the infants were only supplied with the starting formula or natural breastfeeding. Results: The primary outcome, 63 64 weight gain, was higher in both formula groups than in the BFD group at 6 and 12 months, whereas no differences were found between STD and INN groups neither at 6 nor at 12 months. Likewise, 65 BMI was higher in infants fed the two formulas compared with the BFD group. Regarding body 66 composition, length, head circumference and tricipital/subscapular skinfolds were alike between 67 68 groups. The INN formula was considered safe as weight gain and body composition were within the normal limits, according to WHO standards. The BFD group exhibited more liquid consistency in the 69 70 stools compared to both formula groups. All groups showed similar digestive tolerance and infant 71 behavior. However, a higher frequency of gastrointestinal (GI) symptoms was reported by the STD 72 formula group (291), followed by the INN formula (282) and the BFD groups (227). There were 73 fewer respiratory, thoracic, and mediastinal disorders among BFD children. Additionally, infants 74 receiving the INN formula experienced significantly fewer general disorders and disturbances than

those receiving the STD formula. Indeed, atopic dermatitis, bronchitis, and bronchiolitis were significantly more prevalent among infants who were fed the STD formula compared to those fed INN formula or breastfed. To evaluate whether there are significant differences between formula treatments, beyond growth parameters, it would seem necessary to examine more precise health biomarkers and to carry out long-term longitudinal studies.

80 Clinical Trial Registration: The trial was registered with Clinicaltrial.gov (NCT05303077) on
81 March 31, 2022, and lastly updated on April 7, 2022.

Keywords: Arachidonic acid (ARA); α-lactalbumin; *Bifidobacterium animalis* subsp. *lactis*,
 BPL1TM; body composition; docosahexaenoic acid (DHA); infant formula; postbiotics: protein;
 safety.

85 **1.- Introduction**

86 Exclusive breastfeeding is the gold standard for infant feeding because it promotes adequate growth and development, excellent nutritional status, and appropriate psychological development. In 87 88 addition, due to the special composition of breast milk in bioactive and immunogenic substances, it 89 effectively protects against numerous infectious diseases, mainly pneumonia and other respiratory 90 infections, diarrhea, and allergic processes. Moreover, breastfeeding promotes an optimal psycho-91 affective mother-child relationship and has a very low cost, practically nil (Ip et al., 2009; Walker, 92 2010;Black et al., 2013;Victora et al., 2016;Ogbu et al., 2021). Indeed, WHO and UNICEF 93 recommend starting breastfeeding within the first hour of birth and being exclusively breastfed for 94 the first 6 months of life (World Health Organization, 2002;2022). However, from the age of 6 95 months, children should begin eating safe and adequate complementary foods while continuing to 96 breastfeed for up to 2 years and beyond (Kramer and Kakuma, 2001).

97 Breastfeeding protects against disease in both developing (Black et al., 2013) and developed 98 countries (Ip et al., 2009) and is beneficial not only for infants but also for mothers. Indeed, 99 breastfeeding may protect later in life against obesity and metabolic diseases (Rameez et al., 100 2019;World Health Organization, 2022). Additionally, breastfeeding is associated with better 101 performance on intelligence tests (Horta et al., 2015;Victora et al., 2015). Furthermore, women who 102 breastfeed have a reduced risk of breast and ovarian cancers (World Health Organization, 2022).

103 Despite worldwide efforts to promote breastfeeding, there are many social factors, especially 104 premature return to work after childbirth and, in some cases, maternal illness, which cause many 105 mothers to abandon breastfeeding prematurely (Balogun et al., 2015). To promote the adequate 106 growth and development of general infants and those who have those conditions, infant formula 107 designed with an optimal nutritional composition is essential. In this regard, different entities such as 108 the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 109 (Koletzko et al., 2005) and the American Academy of Paediatrics (AAP) have established various 110 recommendations for the composition of infant formulas. In addition, various governmental 111 organizations, such as the FAO/WHO Codex Alimentarius Commission (CODEX ALIMENTARIS, 112 2020), the European Union Commission (Commission Delegated Regulation (EU) 2016) and the US Food and Drug Administration (FDA) (FOOD AND DRUG ADMINISTRATION, 2018) have 113 114 established strict compositional and control standards for infant formula foods to protect the health of 115 consumers and ensure fair practices in the food trade.

116 Continuous research on the composition of human milk and the biological effects of its components

118 five decades, incorporating various food ingredients to meet not only the nutritional needs of infants 119 but also to contribute to better development and functionality (Carver, 2003). Thus, based on certain 120 studies suggesting that a high protein intake in the early stages of life may be the cause of obesity and 121 increased risk of metabolic disease in later stages of life (Brands et al., 2014; Zheng et al., 2018), the protein composition of infant formulas has been adjusted both in quality and quantity, reducing the 122 123 protein intake of infants (Weber et al., 2014; Totzauer et al., 2018;Kouwenhoven et al., 2021). 124 Regarding the quality of protein intake, the whey/casein ratio in infant formulas is important for the 125 first year of life. Whey proteins, both β -lactoglobulin and α -lactalbumin, are rapidly digested and 126 participate in the building of muscle mass (Boirie et al., 1997), being the α -lactalbumin the major 127 protein in human milk (Liao et al., 2017). Therefore, development of infant formula containing 128 bovine α-lactalbumin may improve the plasma amino acid pattern of the receiver infant, allowing a 129 reduction in the protein content of the formula. On the other hand, the relatively high content of long-130 chain polyunsaturated fatty acids of both the n-6 and n-3 series, especially arachidonic acid (AA, 131 20:4 n-6) and docosahexaenoic acid (DHA, 22:6 n-3) in human milk and their proven effects on the 132 cognitive development of infants, has led to the incorporation of these fatty acids into infant 133 formulas. In this regard, and even though EFSA and the European Union Commission have 134 established mandatory compositional recommendations only for DHA content (EFSA Panel on 135 Dietetic Products and Allergies, 2014;EU Commission, 2016), numerous researchers have argued 136 and established consensus documents on the need for infant formulas to incorporate both AA and 137 DHA in amounts comparable to the average composition of human milk. Hence, according to some 138 studies infant formula should provide DHA at levels of 0.3% to 0.5% by weight of total fatty acids 139 and with a minimum level of ARA equivalent to the DHA content (Koletzko et al., 2020;Campoy et 140 al., 2021). Therefore, the supplementation of infant formulas with both DHA and ARA in appropriate 141 amounts should be clinically tested.

142 During the last two decades, advances in the knowledge of the composition of the intestinal 143 microbiome of breast-fed infants and its beneficial effects on the host (Flaherman et al., 144 2018;Gopalakrishna and Hand, 2020) have led to the incorporation of both prebiotics and probiotics 145 in infant formulas (Thomas et al., 2010;Braegger et al., 2011). In this regard, improvements in the 146 prevention of acute infectious diarrhea, treatment of antibiotic-associated diarrhea and prevention of 147 allergy have been reported (Thomas et al., 2010; Braegger et al., 2011; Szajewska et al., 148 2016; Adjibade et al., 2022). Also, it is known that not only live probiotics but also their fermentation 149 products and death cells derived from inactivated probiotics, referred to by the International 150 Scientific Association of Probiotics and Prebiotics (ISAPP) as postbiotics, can exert biological effects of interest on the intestinal microbiota (Salminen et al., 2021; Vinderola et al., 2022). In this 151 context, Bifidobacterium animalis subsp. lactis CECT 8145 inactivated by heat (BPL1TM HT) 152 153 exhibits several biological effects of interest such as reduction in fat deposition via the IGF-1 154 pathway in mice (Balaguer et al., 2022) and has anti-obesity effects in obese Zucker rats (Carreras et al., 2018). Moreover, daily consumption of the living strain BPL1TM ameliorates several 155 anthropometric adiposity biomarkers in abdominally obese adults (Pedret et al., 2019). Likewise, an 156 infant formula supplemented with BPL1TM HT reduced fat deposition in *C. elegans* and augmented 157 158 acetate and lactate in a fermented infant slurry (Silva et al., 2020).

Novel infant formulas should be thoroughly evaluated to ensure their safety, efficacy, and tolerability. Hence, in the present study, we aimed to evaluate the effect of a novel starting infant formula on weight gain, body composition, safety, and tolerability, in infants up to 6 and 12 months of age. This was compared with standard infant formula. Safety and tolerability outcomes included digestive tolerance (flatulence, vomiting and regurgitation), stool appearance (consistency and frequency), behavior (restlessness, colic, nocturnal awakenings), and incidence of infections. Safety

objectives included any frequency of GI symptoms resulting from the consumption of the study formula. As a further exploratory objective, we compared weight gain up to 6 and 12 months and changes in the other secondary outcomes among the infants who received the modified starter formula and the standard formula with a group of exclusively breastfed infants. The complete design and methodology of this randomized, multicenter, double-blind, parallel, comparative clinical trial has been previously registered with Clinicaltrial.gov (NCT05303077) on March 31, 2022, and lastly

- 171 updated on April 7, 2022, and published (Ruiz-Ojeda et al., 2022).
- 172

173 **2.- Material and methods**

174 2.1. Ethics

This clinical trial was carried out following the recommendations of the International Conference on 175 176 Harmonization Tripartite on PCBs, the ethical-legal principles established in the latest revision of the 177 Declaration of Helsinki, as well as the current regional regulations that regulate pharmacovigilance 178 and food safety. The present study was approved by the Committee for Technical Investigation in 179 Regional Medicine in the Madrid Community (CEIm-R) dated 11/05/2018 under the name 180 INNOVA2020 version 2.0. All personal data obtained in this study are confidential. They were 181 treated under the Spanish Organic Law 3/2018, of December 5, on the Protection of Personal Data 182 and guarantee of digital rights. The researchers or the institutions implicated in the study allowed 183 direct access to the data or source documents for monitoring, auditing, and review by the CEIm-R. 184 They also allowed inspection of the trial by the health authorities.

185 2.2. Trial design

The INNOVA study was designed as a randomized, multi-center, double-blind, parallel, and comparative clinical trial of the equivalence of two starting infant formulas for infants. Furthermore, a third un-blinded group of breastfed infants was used as a further reference group for exploratory analysis. Blinding for both investigator and participant remained assured as both infant formulas were labeled the same. It is not mandatory to carry out specific clinical tests to demonstrate the nutritional and healthy properties of infant formulas as per the current EU legislation (EC Regulation No. 1924/2006) (Ruiz-Ojeda et al., 2022).

193 Parents were informed by pediatricians involved in the study of the possibility of participating in it at 194 a meeting at 15 days of infant age. After accepting to participate, they came to the health center for the baseline visit a week later (visit at 21 days of age). The pediatrician requested, at the meeting at 195 196 15 days of life, that parents provide at the next visit relevant information from the maternal history 197 that was required for the study and that was not available in the pediatric history. The visit that took 198 place within the scheduled time was considered valid with a margin of ± 3 days in the visit at 21 days 199 of age, ± 1 week in the visit at 2 months of age, and ± 2 weeks in visits at 4, 6 and 12 months of age. 200 The inclusion criteria were healthy children of both sexes; term children (between 37 and 42 weeks 201 of gestation), birth weight between 2500-4500 g, single delivery, and mothers with a body mass index, before pregnancy, between 19 and 30 kg/m². The exclusion criteria were, body weight less 202 than the 5th percentile for that gestational age at the time of the inclusion, allergy to cow's milk 203 204 proteins and/or lactose, history of antibiotic use during the 7 days before inclusion, congenital disease 205 or malformation that can affect growth, diagnosis of disease or metabolic disorders, significant 206 prenatal and/or severe postnatal disease before enrollment, minor parents (younger than 18 years 207 old), newborn of a diabetic mother, newborn of a mother with drug dependence during pregnancy,

208 newborn whose parents/caregivers cannot comply with procedures of the study, and infants 209 participating or have participated in another clinical trial since their birth. Participants had the right to 210 withdraw from the study at any time and for any reason, without giving explanations or suffering any 211 penalty for it. Likewise, the investigator could withdraw study participants if they did not comply 212 with the study procedures. This is for any reason that, in the investigator's opinion, may pose the 213 infants at risk or makes it necessary to suspend breastfeeding. Children who received antibiotics 214 during the 7 days before inclusion were not considered eligible for the study and, children who 215 received antibiotics during the trial, were excluded: Any treatment, food or product that could 216 interfere with the trial at any time, and breasfeeding which was different from that of the group 217 assigned group in the trial.

218 The sample size of the trial is 210 children (70/group), based on the main outcome of weight gain, 219 which is the main variable chosen according to the guidelines "Guidelines from the American 220 Academy of Pediatrics Task Force on Clinical Testing of Infant Formulas" (Task force on clinical 221 testing of infant formulas committee on nutrition. American Academy of Pediatrics Committee on 222 Nutrition et al., 1988). The infants were selected by Primary Care pediatricians through active and 223 consecutive recruitment i.e. pediatricians informed and invited parents of 15-day-old infants not 224 being breasfed for some reasons to be involved in the trial (see details below under item 2.3). The 225 study was carried out in 21 centers, all located in Spain, of which 17 recruited at least one subject. In 226 total, 217 subjects signed the informed consent (IC) and 145 were randomized to receive one of the 227 two infant formulas. Of these 145, 3 were randomization failures and 2 were screening failures, thus 140 infants who met all the inclusion criteria and no exclusion criteria were included in the study, 228 229 and 70 were unblinded within infants exclusively breastfed. A total of 185 subjects completed all 230 study visits, of which there were 25 dropouts, 12 in the breastfeeding group, 8 in the formula 1 group, 231 and 5 in the standard formula group. The trial was registered with clinicaltrial.gov website 232 (NCT05303077, https://clinicaltrials.gov/ct2/show/NCT05303077) on March 31, 2022, and lastly 233 updated on April 7, 2022 (Ruiz-Ojeda et al., 2022). The inclusion period started in October 01, 2018; and the follow-up period was between February 11, 2019 and November 25, 2020. 234

- 235 2.3 Formula characteristics
- •Group 1 (Infant formula 1): Nutribén[®] Innova 1
- •Group 2 (Infant formula 2): Nutribén® Standard
- •Group 3: Breastfeeding (External control exploratory analysis)

239 Infants were recruited from Primary Care Pediatrics clinics by the pediatricians participating in the 240 trial. Pediatricians informed and invited parents of 15-day-old infants who visited their offices 241 regularly (for regular medical check-ups) to be involved in the trial. Infants that not receive 242 breastfeeding at the time of inclusion (for different reasons) were proposed to participate in the 243 formula-feeding groups. To keep the three arms of the trial balanced, one candidate breastfeeding 244 subject was recruited at each center for every two infants supplemented with infant formula. The selection of the children was made among those infants who met the inclusion and exclusion criteria 245 of the study and fit the categories of sex, body mass index (BMI) of the mother before pregnancy 246 $(<25 \text{ kg/m}^2 \text{ or } >25 \text{ kg/m}^2)$, and birth weight (<3500 g or >3500 g). 247

The experimental product object of this trial (Formula 1 or Nutribén® Innova 1, INN formula) and the Nutribén® Standard formula (STD formula) comply with the recommendations of the ESPGHAN (European Society of Pediatric Gastroenterology, Hepatology and Nutrition) and with

251 Regulation 609/2013 of the European Parliament and of the Council regarding foods intended for 252 children, infants and young children, foods for special medical purposes and complete diet substitutes 253 for weight control and repealing Council Directives 92/51, Directives 96/8/EC, 1999/21/CE, 254 2006/125/CE and 2006/141/CE of the Commission, Directive 2009/38/CE of the European 255 Parliament and of the Council and Regulations 41/2009 and 953/2009 of the Commission. More detailed information on the composition of each of the products can be found in Table 1. Infant 256 257 formulas are given ad libitum orally. The two trial formulations were administered following the 258 preparation instructions in the manufacturer's package insert. DHA was obtained from purified and 259 concentrated fish oil.

260

261	Table 1. Nutritional	composition	of the standa	rd infant formula	(STD) and stud	y formula (I	INN).
201		composition	or the standa		(DID) and brad	<i>j</i> 101111010 (1	<u>.</u>

Composition	STD formula			INN formula		
Composition	100 g	100 mL	100 kcal	100 g	100 mL	100 kcal
Energy (kcal)	514	67		489	67	
Energy (kJ)	2152	280		2046	279	
Total Fat (g)	27	3.5	5.2	25.6	3.5	5.2
Linoleic acid (\Box -6) (mg)	3.79	493	736	3.147	427	641
α -linolenic acid (\Box -3) (mg)	500	65	97	387	53	79
Arachidonic acid AA (\Box -6) (mg)	53	6.9	10	118	16	24
Docosahexaenoic acid DHA (□-3) (mg)	53	6.9	10	118	16	24
Carbohydrates (g)	56.4	7.3	11	54.6	7.4	11.1
Total sugars (g)	56.4	7.3	11	53	7.2	10.8
Lactose (g)	55	7.2	10.7	53	7.2	10.8
Galacto-oligosaccharides (g)	3.1	0.4	0.6	2.9	0.4	0.6
Proteins (g)	10.6	1.4	2.1	9.4	1.3	1.9
Whey proteins (g)	6.4	0.83	1.2	6.6	0.9	1.3
Caseins (g)	4.2	0.55	0.82	2.8	0.38	0.57

262 2.4 Measurements and evaluations

263 2.4.1 Anthropometric measures

264 Weight, length, head circumference, body mass index, body fat percentage, and lean body mass 265 measurements were taken at all study visits (visit 1, 21 days, visit 2, 2 months, visit 3, 4 months, visit 266 4, 6 months, and visit 5, 12 months). Fat mass was estimated by the skinfold measurements. From the visit scheduled for the fourth month of life, the mean arm circumference, the triceps skinfold, and the 267 268 subscapular skinfold were added to the previous measurements. All these measurements were done in 269 duplicate. Using as valid data the mean between the two. Each center had all the necessary materials 270 to carry out these measurements. They needed to always use the same material with all subjects and, 271 of course, the material should be calibrated.

272 2.4.2 Characteristics of feces and digestive tolerance

- 273 We evaluated consistency and the number of stools/day) at times 21 days, 2, 4, 6 and 12 months of
- age Flatulence, vomiting and regurgitation at times 21 days, 2, 4, 6 and 12 months of age were also
- assessed.
- 276 2.4.3 Infant's behavior evaluated by parents
- Restlessness, colic, and night awakenings were evaluated during 21 days, 2, 4, 6 and 12 months of age for the parents. More details are available in the study protocol (Ruiz-Ojeda et al., 2022).
- 279 2.4.4 Morbidity, safety and tolerability

Variables related to morbidities were evaluated within 1-year. All morbidities were coded accordingto MedDRA dictionary version 21.0 (MedDRA, 2018).

282 2.5 Statistical methods

283 The main objective of the study was to evaluate whether the weight gain was equivalent between 284 treatment groups receiving formula 1 and 2, and it has been decided that the sample size of the trial is 285 210 children (70/group) based on the primary variable weight gain (the primary variable selected), 286 following the "Guidelines from the American Academy of Pediatrics" issued by the Task Force on 287 Clinical Testing of Infant Formulas of the American Academy of Pediatrics (Task force on clinical 288 testing of infant formulas committee on nutrition. American Academy of Pediatrics Committee on 289 Nutrition et al., 1988). Previous studies carried out on children fed from 0 to 6 months with different 290 formulations of infant formula have shown a mean weight gain of around 20-25 g/day with a 291 standard deviation between 5 and 6 g/day (Bosheva et al., 2022). In most of these studies, a 292 difference in mean weight gain of 3 g/day was considered clinically relevant. Thus, the main 293 objective was resolved by using a t-test for independent samples. Considering a power of 80%, a 294 significance level of 5%, an equivalence limit of 3 g/day, and a common standard deviation of 5.5 295 g/day, we needed to recruit at least 59 children in each of the groups. Based on an estimated dropout 296 rate of 20%, it was necessary to include 70 children in each of the groups, which means 140 infants. 297 A third group of the same size (70 children) was included for the secondary comparisons between the 298 bottle-fed and breastfed groups, maintaining the same significance and power in this secondary 299 comparison as in the main comparison. Categorical variables are described as frequencies or 300 percentages. Continuous variables are reported as mean and standard deviation. Between-group 301 differences in measures of growth and body composition are analyzed using analysis of variance, 302 including analysis of covariance and general models of analysis of variance for repeated measures 303 (GLM-ANOVA and MANOVA) when required. The Chi-square test is applied to compare discrete 304 variables between groups. The Bonferroni correction is used when comparisons are made between 305 more than two groups. The alpha level of significance is set at 0.05. All evaluable infants have been 306 included in the statistical analysis, considering "evaluable" all those who have the main measurement 307 variable. Both, intention to treat and protocol-based statistical analyses are performed.

308 **3.- Results**

Table 2 shows demographic and descriptive information for infants and their mothers. Here, gestational age, birth weight, childbirth delivery, assisted reproductive technology, and the mother's medical background were included, though no significant variables were shown. During visit 1 (21 days), only daily depositions per day were significantly higher for the BFD group in comparison with

313 formula groups.

314 The parents or legal guardians returned to the center all the leftover containers (empty containers and 315 containers with products) to record the amount of product dispensed and the amount of infant 316 formula used up to the time of the visit; the corresponding weighing was performed and the 317 percentage of product ingested by the participants was determined. Finally, the grams of formulation 318 consumed by each infant, measured by weighing the leftover formulations or as indicated in the 319 parents' diary corresponding to the periods between visits 1-2, 2-3 and 3-4, were available. The 320 participants of this study included in the formula-feeding groups were considered compliant if they 321 took at least 80% of the formula during the first six months while in the breastfeeding group it was 322 considered a valid external control if more than 80% of the feedings were breastfeeding. All infants 323 included in the BFD group, except one, consumed more than 80% of human milk during the first six 324 months.

Based on the record of the amount of product dispensed and the amount of infant formula used (measurement of leftover) we estimated the average daily intake from visits 1 to 4 for the STD group (130.2 \pm 14.7 g/d, equivalent to 671 \pm 76 kcal/d of energy and 13.8 \pm 1.56 g/d of protein) and the INN group (134.0 \pm 18.2 g/d, equivalent to 655 \pm 89 kcal/d of energy and 12.60 g/d of protein).

A GLM-ANOVA was performed for grams of formula consumed per day, and significant differences were observed for visit, sex and infant birth weight, but not about the formula used (data not presented).

332

Table 2. Baseline demographics of the infants in the study

	BFD	STD	INN	P-value
N	70	70	70	
Gender (% of women)	28 (40.0)	29 (41.4)	33 (47.1)	0.738
Gestational age (weeks)	39.44 (1.1)	39.20 (1.1)	39.34 (0.9)	0.389
Birth weight (g)	3359.20 (403.9)	3300.87 (462.9)	3363.30 (408.7)	0.626
Birth weight >3500 g (%)	22 (31.4)	22 (31.4)	27 (38.6)	0.613
Childbirth delivery n, (%)				0.579
Cesarean section	13 (18.6)	17 (24.3)	20 (28.6)	
Distocyc	8 (11.4)	6 (8.6)	9 (12.9)	
Normal childbirth	49 (70.0)	47 (67.1)	41 (58.6)	
Assisted reproductive technology n, (%)	4 (5.7)	6 (8.6)	3 (4.3)	0.679
Assisted reproductive technology type (%)				0.066
In vitro fertilization	1 (25.0)	6 (100.0)	2 (66.7)	
Artificial insemination	2 (50.0)	0 (0.0)	1 (33.3)	
Egg donation	1 (25.0)	0 (0.0)	0 (0.0)	
Maternal BMI (kg/m²), (x, SD)	23.72 (3.2)	23.92 (3.3)	23.78 (3.0)	0.967
BMI mother>25 n, (%)	22 (31.4)	22 (31.4)	24 (34.3)	0.85
Mother's medical background n, (%)				0.849
Allergy	0 (0.0)	0 (0.0)	2 (2.9)	
Hypothyroidism	7 (10.0)	5 (7.1)	4 (5.7)	
Arterial hypertension	0 (0.0)	2 (2.9)	1 (1.4)	
No	58 (82.9)	55 (78.6)	55 (78.6)	

Others	5 (7.1)	8 (11.4)	8 (11.4)	
Visit 1, (21 days)	BFD	STD	INN	P-value
Depositions per day	5.2 (3.2)	2.5 (2.0)	2.3 (1.4)	< 0.001*
Weight	3921.8 (475.5)	3805.0 (507.5)	3916.6 (453.9)	0.268
Length	53.1 (1.9)	52.6 (2.2)	52.8 (1.7)	0.287
Head circumference	36.6 (1.0)	36.2 (1.3)	36.5 (1.2)	0.214

333

Data are expressed as mean and standard deviation, and frequency or percentage. BMI, body mass index; NS, non-significant

334

Table 3. Differential daily	weight gain and absolute	e weight in the entire study	ŗ
-		() /	

Differential daily weight gain per day (g)							
Groups	BFD	STD	INN		P-value		
Differential daily weight gain	(N=58)	(N=65)	(N=62)	STD vs. BFD	INN vs. BFD	STD vs. INN	
Visit 4 vs Visit 1	22.0 ± 4.6	24.24 ± 5.06	24.60 ± 5.29	0.01	0.004	0.693	
Visit 5 vs visit 1	16.01 ± 2.66	17.41 ± 3.25	17.00 ± 2.95	0.011	0.057	0.457	
		We	eight (g)				
Groups	BFD	STD	INN		P-value		
Weight	(N=58)	(N=65)	(N=62)	Formula	Visit	Formula x visit	
Visit 1, 21 days	3951.3 ± 498.0	3805.8 ± 509.6	3916.9 ± 468.7				
Visit 2, 2 months	5285.1 ± 564.9	5193.7 ± 684.0	5236.6 ± 623.2				
Visit 3, 4 months	6558.6 ± 697.1	6733.0 ± 937.7	6843.1 ± 855.1	0.081	0.848	0.011	
Visit 4, 6 months	7471.1 ± 846.3	7718.7 ± 1132.8	7903.1 ± 1063.5				
Visit 5, 12 months	9505.2 ± 985.6	9869.7 ± 1382.1	9797.6 ± 1234.4				

335

Data are expressed as mean \pm standard deviation

336 The primary variable (weight gain) consisted of the difference in infant weight (in g/day) between the 337 initial recruitment visit and the 6-month visit, divided by the number of days between the two visits. 338 This analysis was performed on the 187 infants who completed until visit 4 (6 months). The 339 difference between visit 1 and visit 4 was calculated in days of 187 children individually (Table 3). 340 When analyzing the mean difference in weight gain between the groups of children treated with the 341 STD and INN formulations (Table 3), there was no statistically significant difference in weight gain 342 between the two formulations. On the other hand, an ANOVA of the weight difference between visits 343 1 and 4 was performed for the STD and INN formulations controlling for the factors, gender, 344 maternal body mass index (BMI) and birth weight. There were significant differences in weight 345 difference between visits 1 and 4 as a function of gender and infant birth weight, but not as a function 346 of formulation or mother's BMI (Table 3). The grams consumed per day were also related to the difference in weight between visits 1 and 4. Based on the weighing of leftover grams of the dispensed 347 348 formulation, a multivariate analysis of variance (MANOVA) of the difference in weight of the children between visits 1 and 4 was performed as a function of formulation consumed (STD, INN), 349 350 gender (male, female), maternal BMI (<25, >25), birth weight (<3500, >3500) and grams ingested 351 per day. A moderate positive correlation (r=0.535) was observed between mean grams ingested per 352 day (measured by weighing leftover formulations) and weight gain between visits 1 and 4 of the 353 infants. This correlation changed significantly by gender (males achieved larger weight differences 354 for the same daily grams of formulation consumed) and by birth weight (infants with birth weights > 355 3500 g achieved larger weight differences for the same daily grams of formulation consumed) but not as a function of maternal BMI or formulation used. 356

This same MANOVA as a function of grams ingested daily according to the parental diary also showed a positive correlation (r=0.626) between mean grams ingested per day (obtained from parental diary entries) and weight gain between visits 1 and 4 of the infants. This correlation changed significantly by gender (boys achieved larger weight differences for the same daily grams of formulation consumed) and by birth weight (children with birth weights > 3500 achieved larger weight differences, especially those who consumed more daily grams of formulation) but not as a function of maternal BMI or formulation used.

Secondarily and foreseen in the study protocol, the weight gain of the infants who received each of the formulations studied was compared with the BFD group. The results of this analysis are shown in **Table 3**, where it can be seen that BFD infants had a significantly lower weight gain at 6 months of age than that shown by infants fed with either of the two formulations evaluated (STD and INN).

The same analysis was performed for the variable weight gain at 12 months of study. **Table 3** shows 368 369 the number of children in each of the 3 groups studied with weight values recorded at visit 1 (21 days 370 of age) and visit 5 (12 months \pm 2 weeks). A comparison of the means of weight gain from the 371 different formulations (STD vs. INN, STD vs. BFD and, INN vs. BFD, Table 3) revealed that at 6 372 months there is no significant difference in weight gain (measured in g/day) as well as at 12 months 373 between the STD and INN formulations. The total weight of the STD formulation group remained 374 significantly higher than the BFD group at 12 months, however, the INN group exhibited a trend to 375 be different from breastfeeding between visits 1 and 5 (p=0.057). A GLM-ANOVA (data not presented) showed significant differences for visit (p<0.001) and for the interaction between 376 377 formulation and visit (p=0.004), but not for formulation exclusively (p=0.381). The largest effect size 378 was associated with the visit factor.

379

Table 4. Length and head circumference in the entire study Length (cm) BFD STD INN Visits (N=65) (N=58) (N=62) 52.49 ± 2.24 Visit 1 53.15 ± 2.08 52.87 ± 1.78 57.95 ± 2.02 Visit 2 57.89 ± 2.42 57.47 ± 2.33 Visit 3 63.16 ± 2.42 63.24 ± 3.67 63.50 ± 2.16 Visit 4 66.68 ± 2.64 67.01 ± 3.26 67.15 ± 2.14 75.44 ± 2.90 75.82 ± 3.08 75.96 ± 2.54 Visit 5 Head circumference (cm) STD BFD INN Visits (N=58) (N=65) (N=62) Visit 1 36.66 ± 1.02 36.22 ± 1.34 36.51 ± 1.25 Visit 2 36.09 ± 1.17 38.87 ± 1.36 39.11 ± 1.63 Visit 3 41.56 ± 1.12 41.79 ± 3.73 41.64 ± 1.39 Visit 4 43.19 ± 1.22 43.18 ± 1.37 43.41 ± 1.45 46.40 ± 1.18 46.25 ± 1.53 46.29 ± 1.50 Visit 5

380

Data are expressed as mean and standard deviation

No significant differences were observed in length and head circumference, as well as, tricipital and subscapular skinfolds and mean upper arm circumference (**Tables 4** and **5**).

- 383
- 384
- 385
- 386

387

388

-	-	-	
~	0	0	

Tricipital skinfold (mm)					
	BFD	STD	INN		
	(N=58)	(N=65)	(N=62)		
Visit 3	12.32 ± 2.26	12.66 ± 2.67	12.78 ± 3.00		
Visit 4	12.35 ± 2.23	12.60 ± 2.65	12.90 ± 2.99		
Visit 5	12.34 ± 2.23	12.63 ± 2.65	12.84 ± 2.99		
	Subscapul	ar skinfold (mm)			
	BFD	STD	INN		
	(N=58)	(N=65)	(N=62)		
Visit 3	9.92 ± 2.69	9.83 ± 2.72	10.25 ± 2.73		
Visit 4	9.90 ± 2.49	9.94 ± 2.72	10.36 ± 2.73		
Visit 5	9.91 ± 2.58	9.89 ± 2.73	10.30 ± 2.72		
	Mean upper arr	n circumference (cm)		
	BFD	STD	INN		
	(N=58)	(N=65)	(N=62)		
Visit 3	13.79 ± 1.30	13.89 ± 1.67	14.15 ± 1.21		
Visit 4	14.41 ± 1.24	14.72 ± 1.46	14.98 ± 1.88		
Visit 5	15.34 ± 1.26	15.29 ± 1.68	15.94 ± 1.39		

Table 5. Tricipital and subscapular skinfolds and mean upper arm circumference in visits 3, 4, and 5. 389

390

Data are expressed as mean and standard deviation

3	Q	1
\mathcal{I}	1	T

Table 6. Body mass index, body fat percentage, and lean mass.

	Body m	ass index (kg/m ²)			P-value	
Visits	BFD (N-58)	STD (N=65)	INN (N-62)	Formula	Visit	Formula x visit
Visit 1	13.94 + 1.11	(11-03) 1375 + 104	(17-02) 13 97 + 1 07			X VISIU
Visit 2	15.74 ± 1.08	15.67 ± 1.30	15.56 ± 1.28			
Visit 3	16.42 ± 1.22	16.97 ± 3.61	16.94 ± 1.59	0.487	< 0.001	< 0.001
Visit 4	16.78 ± 1.30	17.15 ± 1.83	17.49 ± 1.81			
Visit 5	16.69 ± 1.28	17.11 ± 1.64	16.94 ± 1.54			
	Body	fat percentage			P-value	
Visits	BFD (N=58)	STD (N=65)	INN (N=62)	Formula	Visit	Formula x visit
Visit 3	19.35 ± 3.53	19.60 ± 3.39	20.37 ± 3.67			
Visit 4	20.36 ± 3.53	20.30 ± 3.73	21.29 ± 3.93	0.249	0.005	0.958
Visit 5	20.84 ± 3.64	21.02 ± 3.82	21.61 ± 4.01			
	Le	ean mass (g)			P-value	
X 7 • •/	BFD	STD	INN		T 7 • •/	Formula
VISIUS	(N=58)	(N=65)	(N=62)	Formula	Visit	x visit
Visit 3	5284 ± 559	5403 ± 709	5436 ± 615			
Visit 4	5942 ± 654	6135 ± 823	6207 ± 782	0.215	< 0.001	0.054
Visit 5	7509 ± 703	7805 ± 1023	7670 ± 967			

392

Data are expressed as mean and standard deviation

393 In the case of BMI, the ANOVA (Table 6) shows significant differences for visit (p<0.001) and for 394 the interaction between formulation and visit (p<0.001), but not for formulation (p=0.487). The 395 largest effect size was associated with the visit factor (0.4230, data not provided). In addition, we

396 have reported that it was from the third visit onwards that the mean BMI was higher in the STD and 397 INN formulations compared to the BFD group; hence, the interaction effect appears as significant 398 (Table 6). For the body fat percentage, the ANOVA (Table 6) shows significant differences for visit 399 (p=0.005), but not for the interaction between formulation and visit (p=0.958) and for formulation 400 (p=0.249). The largest effect size is associated with the visit factor (0.0236, data not shown). Finally 401 for the lean mass, the ANOVA (**Table 6**) shows significant differences for visit (p < 0.001), but not 402 for the interaction between formulation and visit (p=0.054) and for formulation (p=0.215). The 403 largest effect size is associated with the visit factor (0.6093, data not provided).

404 In the case of BMI percentiles, the ANOVA (Table S1) reveals significant differences for visit 405 (p=0.009) and the interaction between formulation and visit (p=0.006), but not for formulation (p=0.504). The largest effect size is associated with the visit factor (0. 0222, data not provided). In 406 407 the ANOVA, there were significant differences in the height percentiles for visit (p=0.011), for the 408 interaction between formulation and visit (p<0.001), but not for formulation (p=0.433, Table S1). 409 The largest effect size is associated with the visit factor (0.0154, data not shown). Finally, in the 410 weight percentiles, the ANOVA (**Table S1**) shows significant differences for visit (p<0.001) and for 411 the interaction between formulation and visit (p<0.001), but not for formulation (p=0.368). The 412 largest effect size is associated with the visit factor (0.0228, data not provided).

413 The time course of the study shows a difference between breastfed infants presenting stools of a more

414 liquid consistency (**Table S2**), although these differences ceased to be significant at visit 5 (see **table**

415 S2). Likewise, the daily number of stools was higher in breastfed infants at visits 1, 2 and 3, but these

416 differences ceased to be significant at visits 4 and 5 (**Table 7**).

417

Table 7. The daily number of stools.

Number of daily depositions	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
		BFD			
Mean (SD)	5.2 (3.2)	3.1 (2.3)	2.3 (1.5)	2.0 (1.4)	1.8 (1.0)
Median [Min, Max]	5 [3, 8]	3 [1, 4]	2 [1, 3]	2 [1, 2]	2 [1, 2]
		STD			
Mean (SD)	2.5 (2.0)	1.5 (0.7)	1.3 (0.6)	1.5 (1.0)	1.9 (0.9)
Median [Min, Max]	2 [1, 4]	1 [1, 2]	1 [1, 2]	1 [1, 2]	2 [1, 2]
		INN			
Mean (SD)	2.3 (1.4)	1.6 (0.8)	1.6 (0.9)	1.6 (0.9)	1.9 (0.8)
Median [Min, Max]	2 [1, 3]	1 [1, 2]	1 [1, 2]	1 [1, 2]	2 [1, 2]

418

Data are expressed as mean and maximum and minimum

- 423
- 424
- 425

Figure 1 shows the tabulation of the different categories of digestive tolerance between every two visits. An increase in the percentage of children with high tolerance is seen throughout the study without significant differences between the different formulations and compared with the BFD group.

426

427 Figure 1



440 Figure 1. Digestive tolerance. Data are presented as percentages (%). BFD, breastfeeding group;
441 STD, standard group; INN, INNOVA group.

The infant's behavior was re-coded as altered mood or pleasant mood according to the guardians or parents. **Table S3** shows how the percentage of infants with altered behavior decreased throughout the study. No significant differences were observed among the three ways of feeding.

The study found no differences in tolerability between the different groups (**Table S4**). According to the safety of the different formulations, the majority of the adverse events (n=754) were mild - Grade 1 (94.3%), 13 were moderate-Grade 2 (1.6% of the total) and none were severe-Grade 3. The intensity was not recorded for 33 of the events (4.1%) (**Table 8**). There were no differences between the different groups concerning the intensity of the events. For example, there were 93.0% of mild events in the BFD group, 91.8% in the INN group, and 97.6% in the STD group.

451

Table 8. Gastrointestinal symptoms across the study

Total adverse events	BFD (N=70)	STD (N=70)	INN (N=70)
Subjects with at least one adverse event (%)	62 (88.6%)	57 (81.4%)	61 (87.1%)
Total number	227	291	282
Mild - Grade 1	211	284	259
Moderate - Grade 2	3	3	7
Severe - Grade 3	0	0	0

Potentially fatal - Grade 4	0	0	0
Lethal - Grade 5	0	0	0
Unknown	13	4	16
Adverse events related to feeding	BFD (N=70)	STD (N=70)	INN (N=70)
Subjects with at least one adverse event (%)	1 (1.4%)	1 (1.4%)	1 (1.4%)
Total number	1	2	2
Mild - Grade 1	1	2	2
Moderate -Grade 2	0	0	0
Severe - Grade 3	0	0	0
Potentially fatal - Grade 4	0	0	0
Lethal - Grade 5	0	0	0
Unknown	0	0	0

452

Data are expressed as counts and percentages

Most of the gastrointestinal symptoms were mild, with 1 growth failure, within the BFD group that led to the introduction of artificial breastfeeding together with breastfeeding, two events, neonatal constipation, and abdominal pain, recorded by one infant within the INN group, led to the change of formula and the abandonment of the study and two (infantile colic and infant reflux) recorded by one infant within the STD group that led to the change of formula and the abandonment of the study (**Table 8**).

For morbidities that occurred with a frequency greater than 1%, BFD infants exhibited the lowest incidence and infants fed INN formula experienced significantly fewer general disorders and disturbances compared with the STD group. Indeed, the infants who were fed STD formula had a significantly higher incidence of atopic dermatitis, bronchitis and bronchiolitis events than the infants who were fed BFD or INN formula. (**Table 9**).

464

Table 9. Morbidities that occur with a frequency greater than 1%.

465

MedDPA dictionary version 21.0	BFD (N=70)		STD (N=70)		INN (N=70)	
(MedDRA 2018)	Case					
(WedDick, 2010)	S	%	Cases	%	Cases	%
Cold	42	18.50	47	16.15	38	13.48
Pyrexia	16	7.05	24	8.25	11	3.90
Bronchitis/Bronchiolitis*	13	5.7	34	11.7	17	6.00
Upper respiratory tract infection	11	4.85	11	3.78	15	5.32
Infantile colic	14	6.17	9	3.09	10	3.55
Conjunctivitis	5	2.20	11	3.78	15	5.32
Neonatal constipation	6	2.64	10	3.44	9	3.19
Acute otitis media	4	1.76	6	2.06	13	4.61
Rhinorrhea	9	3.96	5	1.72	6	2.13
Gastroenteritis	4	1.76	8	2.75	8	2.84
Cough	9	3.96	7	2.41	5	1.77
Vaccination complication	1	0.44	10	3.44	7	2.48
Laryngitis	1	0.44	9	3.09	7	2.48
Atopic dermatitis*	1	0.44	11	3.78	2	0.71
Seborrheic dermatitis	2	0.88	4	1.37	5	1.77

Neonatal diarrhea	2	0.88	3	1.03	5	1.77
Oral candidiasis	4	1.76	3	1.03	2	0.71
Nasopharyngitis	1	0.44	2	0.69	6	2.13
Infantile eczema	1	0.44	5	1.72	2	0.71
Diaper dermatitis	2	0.88	2	0.69	4	1.42
Rash	3	1.32	2	0.69	2	0.71
Neonatal disorder	2	0.88	1	0.34	4	1.42
Upper respiratory tract infection	2	0.88	1	0.34	3	1.06
Wheezing	2	0.88	3	1.03	1	0.35
Infant reflux	1	0.44	2	0.69	3	1.06
Otitis media	4	1.76	1	0.34	1	0.35
Gastroesophageal reflux disease	4	1.76	0	0.00	1	0.35
Heart murmur	4	1.76	1	0.34	0	0.00
Diarrhea	1	0.44	0	0.00	4	1.42
Atopic Dermatitis*	1	0.44	3	1.03	0	0.00
Traumatic head injury	0	0.00	1	0.34	4	1.42
Abdominal pain	0	0.00	1	0.34	3	1.06
Bronchial hyperreactivity	0	0.00	3	1.03	0	0.00
Decreased appetite	0	0.00	3	1.03	0	0.00
Pharyngotonsillitis	0	0.00	1	0.34	3	1.06
Umbilical hernia	0	0.00	1	0.34	3	1.06
Viral rash	0	0.00	1	0.34	3	1.06
Traumatic injury to the mouth	1	0.44	0	0.00	3	1.06
Total	1	73	2	46	22	25

466

467 Data are expressed as counts and percentages, *p<0.05 BFD and INN vs. STD group. For the analysis, the Chi-square test was used 468 with the Yates correction where appropriate. Bronchitis/bronchiolitis showed a p-value of 0.029 (BFD vs STD), 1.0 (BFD vs INN),

469 and 0.026 (STD vs INN). Atopic dermatitis exhibited a p-value of 0.027 (BFD vs STD), 1.0 (BFD vs INN), and 0.029 (STD vs INN)

470 **4.- Discussion**

471 The present randomized, double-blind, placebo-controlled clinical trial was designed to determine 472 whether a novel starting infant formula with reduced protein content, lower casein to whey protein ratio by increasing the content of α -lactalbumin, influenced weight gain and body composition 473 compared to a standard formula at 6 and 12 months of age. Furthermore, this product contains higher levels of DHA and ARA, as well as a postbiotic thermally inactivated (BPL1TM HT), compared with 474 475 standard infant formula. An exclusively breastfed population was followed-up as a reference. At 6 476 and 12 months, infants receiving either INN or STD formula gained more weight than the BFD 477 478 group, while no difference was observed between STD and INN formulas. BMI was also higher in 479 infants fed both formulas than in those breastfed. Regarding body composition, length, head circumference, and tricipital/subscapular skinfolds, we found that all of the measures were similar 480 between all groups. It is important to note that the INN formula was considered safe based on weight 481 482 gain and body composition, which were within the normal limits, according to WHO standards. Compared to both formulas, BFD produced stools that were more liquid in consistency. Throughout 483 484 the study period, all groups exhibited similar digestive tolerance and infant behavior. In terms of the 485 total number of adverse events reported, the STD formula had the highest number, followed by the INN formula and finally, the BFD group. However, the majority of them were not related to the type 486 of feeding. Besides, infants fed either BFD or the INN formula exhibited significantly lower episodes 487 488 of atopic dermatitis, bronchitis and bronchiolitis events than those fed the STD formula.

489

490 In addition to exposure to metabolic and endocrine factors during pregnancy (Monasta et al., 2011), 491 protein intake in formula-fed infants during the first year of life may have a significant impact on 492 growth later in life and the risk of obesity and metabolic disorders in adulthood (Koletzko et al., 493 2009; Zheng et al., 2018). Indeed, the protein content of infant formula is usually greater than that of 494 human milk to provide all essential amino acids in adequate quantities (Davis et al., 2008). Scientific 495 evidence indicates that infants fed a formula containing more protein gain more weight during the 496 first year of life and are heavier at 2 years of age than infants consuming a formula containing less 497 protein (Koletzko et al., 2009), which reduces the risk of obesity at school age (Weber et al., 2014). 498 In our RCT, infants fed either INN or STD formula gained more weight than the breastfed group at 6 499 months as measured by differential daily weight gain per day (g). Similar results have been reported 500 in other earlier studies (Baird et al., 2008) even with a relatively low content of protein (Timby et al., 501 2014). However, previous studies on formulas with a reduced protein-energy ratio of up to 1.8 g/100502 kcal have shown more modest differences in growth patterns compared with infants breastfed, similar ot our findings (Räihä et al., 2002;Koletzko et al., 2009;Ren et al., 2022), which supports the 503 504 hypothesis that the protein-energy ratio plays a key role for weight gain. In our study the intake of 505 INN formula was slightly higher than the STD formula, thus compensating for the lower energy 506 content and protein of the former. Compensation for lower energy density and protein has been 507 reported in other studies (Timby et al., 2014). After 12 months, the STD group was significantly 508 higher than BFD and INN groups. We should note that the INN formula contains 8% less protein per 509 100 kcal than the STD. Thus, in the first six to eight weeks of life, there is almost no difference 510 between breast milk and formula-fed infants in terms of growth (gain in weight and length). Indeed, 511 it has been previously reported that formula-fed infants gained weight and length more rapidly than breast-fed infants from about two months of age to the end of their first year of life (Ziegler, 2006). 512 513 Interestingly, the results of a recent review suggest that the difference in weight gain between 514 formula-fed and breastfed infants is relatively small, comparable, and significantly less than the nutritionally significant differences used in determining sample size (Wallingford and Barber, 2019). 515

516 In addition to the total protein content, the whey/casein ratio in infant formulas seems to be important for the first year of life. Whey proteins, particularly β -lactoglobulin and α -lactalbumin, are rapidly 517 518 digested and participate in the building of muscle mass (Boirie et al., 1997), and particularly, α -519 lactalbumin is the major protein in human milk (Liao et al., 2017). Thus, the addition of bovine α -520 lactalbumin to infant formula modifies the plasma amino acid pattern of the receiver infant, allowing 521 a reduction in the protein content of the formula. On the other hand, casein proteins are water-522 insoluble high molecular weight molecules that are a source of phosphate and calcium in human 523 milk, because of the highly phosphorylated nature of β -casein and α -S1-casein, and the requirement 524 for calcium in forming the aggregates of casein micelles (Poth et al., 2008). Nevertheless, the amount 525 should be controlled to avoid improper digestion in early life. In this context, using cow's milk as the 526 protein source in infant formula might result in an α -casein-dominant formula, which differs from the 527 whey protein dominance in human milk. Further, bovine whey contains a high concentration of β -528 lactoglobulin, which is absent in human milk (Jackson et al., 2004), therefore, adding bovine α -529 lactalbumin to infant formula makes it more similar to that of breastfed infants (Lönnerdal and Lien, 2003). Moreover, α -lactalbumin is relatively rich in tryptophan, which may result in satisfactory 530 531 growth and plasma tryptophan levels similar to those of breastfed infants and infants fed standard 532 formula (Sandström et al., 2008). Nevertheless, in our study, both formula-fed infants gained weight 533 more rapidly compared with exclusively breastfed infants, and there was no significant difference 534 between the groups in terms of length, head circumference, tricipital and subscapular skinfolds, and 535 upper arm circumference, suggesting that both formulas causes similar body composition in infants.

536 The proportion of fatty acids present in infant formulas is important to ensure the correct growth and 537 development of infants. In the last 20 years, formulas have been supplemented with LC-PUFA in amounts similar to breast milk. Despite the new EU regulation that indicates that AA is not needed to 538 539 be included, intervention studies assessing the impact of DHA- and AA-supplemented formulas have 540 resulted in numerous positive developmental outcomes (closer to breast-fed infants) including 541 measures of specific cognition functions, visual acuity, and immune responses (Forsyth et al., 542 2017; Jasani et al., 2017; Lien et al., 2018). AA has different biological functions compared to DHA, 543 for example, AA has exclusive functions in the vasculature and specific aspects of immunity. 544 Undeniably, most of the trials include both DHA and AA, and test development specific to DHA 545 such as neural and visual development. DHA suppresses membrane AA concentrations and its 546 function. Infant formula with DHA and no AA runs the risk of cardio and cerebrovascular morbidity 547 and even mortality through suppression of the favorable oxylipin derivatives of AA (Crawford et al., 548 2015). International expert consensus suggests that infant formulas that contain DHA at a concentration of 0.3% to 0.5% by weight of total fat and AA at a minimum level equivalent to the 549 550 amount of DHA should be clinically tested (Koletzko et al., 2020; Campoy et al., 2021). In this study, 551 we used an advanced formula enhanced with a double amount of DHA/AA in comparison with a 552 STD formula to provide evidence about weight gain and body composition, among other outcomes. 553 Throughout the study, the percentage of children with high tolerance increased without significant 554 differences between formulations and compared to the group receiving BFD. According to the 555 guardians or parents, the infant's behavior was classified as altered mood or pleasant mood. There 556 was a decrease in the number of infants with altered behavior throughout the study. The three 557 methods of feeding did not show any significant differences.

The INN formula was also supplemented with a thermally inactivated postbiotic Bifidobacterium 558 animalis subsp. lactis, BPL1TM (Carreras et al., 2018;Nataraj et al., 2020), which may confer some 559 560 benefits regarding body composition, metabolism, and gut microbiota composition. Probiotics have 561 many health benefits by modulating the gut microbiome; nonetheless, techno-functional limitations 562 have made it gradually shift from viable probiotic bacteria towards non-viable postbiotics, paraprobiotics and/or probiotics-derived biomolecules, so-called postbiotics (Nataraj et al., 2020). 563 Since the experimental formula of the present study was supplemented with BPL1TM HT, it should be 564 noted that in vivo studies reported that this strain can be considered a Generally Recognized as Safe 565 (GRAS) substance. In terms of the intensity of GI symptoms, tolerability and safety, there were no 566 567 differences between the different groups (BFD, STD and INN formula). In different contexts and 568 using different methods, infants are fed a variety of products. The formula for infants is available in 569 many variations, many of which are superior to other methods of feeding and some of which are 570 inferior to others. On the other hand, there was a significant difference between BFD group 571 presenting stools of a more liquid consistency, although this difference no longer existed at visit five 572 (12 months). Additionally, BFD infants had more stools per day at visits 1, 2, and 3, but these 573 differences ceased to be significant at visits 4 and 5. STD formula group reported the most of GI 574 symptoms, followed by the INN formula and BFD group. There were no differences in safety across the study between the different groups. Several differences were observed between the two formulas, 575 576 showing a significant reduction in general disorders and disturbances among children who received the INN formula. STD formula-fed infants were more likely to cause atopic dermatitis, bronchitis, 577 578 and bronchiolitis than BFD or INN formula-fed infants. Eczema or atopic dermatitis is a common 579 chronic inflammatory skin disease, mostly occurring in children. Indeed, a meta-analysis showed that 580 probiotic supplementation during both the prenatal and the postnatal period reduced the incidence of 581 atopic dermatitis in infants and children, suggesting that starting probiotic treatment during gestation 582 and continuing through the first 6 months of the infant's life may be of benefit in the prevention of 583 atopic dermatitis (Li et al., 2019). In this context, a study demonstrated that prenatal and postnatal

supplementation with a mixture of *B. bifidum* BGN4, *B. lactis* AD011, and *L. acidophilus* AD031 is an effective approach in preventing the development of eczema in infants at high risk of allergy during the first year of life (Kim et al., 2010). Hence, the lower incidence of atopic dermatitis observed in the INN formula group compared to the STD group might be mediated by the supplementation of the postbiotic BPL1TM HT. Likewise, respiratory tract infections represent one of the main health problems in children of different ages (Vesa et al., 2001). Finally, changes in the intestinal microbiota will need to be assessed.

591 There are some limitations for this study. There were no significant correlations between the type of 592 feeding and the number of adverse events. Nevertheless, the number of infants in the present study 593 was calculated for the growth as the main variable and not for the morbidity.

594 In conclusion, this clinical trial involved the evaluation of a novel infant formula with reduced 595 content of total protein and modification of the whey/casein ratio by increasing the content of a-596 lactalbumin, increased levels of both AA and DHA, and postbiotic in comparison with standard 597 infant formula. For exploratory analysis, a third unblinded group of breastfed infants was used. Both 598 formulas gained more weight at 6 and 12 months than the BFD group, while no differences were 599 observed between STD and INN formulas. Infants fed both formulas had a higher BMI than those fed 600 BFD. Body composition, head circumference, and tricipital/subscapular skinfolds were similar 601 between the two groups. We should note that the INN formula is safe and it showed a reduction in 602 atopic dermatitis, bronchitis, and bronchiolitis in infants compared to STD formula. The consistency 603 of the stools produced by BFD was more liquid in comparison with both formulas. For further 604 analysis, it would be necessary to examine more precise health biomarkers and to carry out long-term 605 longitudinal studies.

606 **Conflict of Interest**

607 Javier Morales is employee at Alter Farmacia S. A. The remaining authors declare that the research

- 608 was conducted in the absence of any commercial or financial relationships that could be construed as
- a potential conflict of interest.

610 Author Contributions

611 AGG, IG and MM were responsible for a careful review of the protocol, design, and methodology.

- 612 FJRO, JPD and AG provided continuous scientific advice for the study and the interpretation of the
- 613 results. These authors also wrote and critically reviewed the manuscript. All authors approved the
- 614 final version of the manuscript.

615 Funding

616 The present study was funded by Alter Farmacia S. A. The funding sponsor had no role in the design617 of the study, the collection, analysis, or interpretation of the data, and the writing of the manuscript.

618 Acknowledgments

We thank to the pediatrician team who participated in this study: Alba Corrales; Alfonso Carmona;
Amalia López; Ana Isabel Rodriguez; Ana Maderuelo; Ana Terrén-Lora; Eduardo Ortega; Esther
Martin; Eva Castillo; Isabel Mayordomo; José Fernando Ferreira; José María Aguilar Diosdado;
Maite Santos-Garcia; Mari Carmen Pino Zambrano; María José Carnicero; Maria Teresa Santos;
Vasilica Doina and Xavier Riopedre. Julio Plaza-Diaz is part of the "UGR Plan Propio de

624 Investigación 2016" and the "Excellence actions: Unit of Excellence on Exercise and Health 625 (UCEES), University of Granada". Julio Plaza-Diaz is supported by a fellowship awarded to 626 postdoctoral researchers at foreign universities and research centers from the "Fundación Ramón 627 Areces", Madrid, Spain.

628 Supplementary Material

629 Supplementary material is expressed as tables and is found in the supplementary file (Tables S1-S4).

630 Data Availability Statement

The datasets used and/or analyzed during the current study are available from the correspondingauthor upon reasonable request.

633 **References**

- Adjibade, M., Davisse-Paturet, C., Divaret-Chauveau, A., Adel-Patient, K., Raherison, C., Dufourg,
 M.N., Lioret, S., Charles, M.A., and De Lauzon-Guillain, B. (2022). Enrichment of Formula
 in Probiotics or Prebiotics and Risk of Infection and Allergic Diseases up to Age 5.5 Years in
 the Nationwide Etude Longitudinale Francaise depuis l'Enfance (ELFE) Cohort. *J Nutr* 152,
 1138-1148.
- Baird, J., Poole, J., Robinson, S., Marriott, L., Godfrey, K., Cooper, C., Inskip, H., and Law, C.
 (2008). Milk feeding and dietary patterns predict weight and fat gains in infancy. *Paediatr Perinat Epidemiol* 22, 575-586.
- Balaguer, F., Enrique, M., Llopis, S., Barrena, M., Navarro, V., Alvarez, B., Chenoll, E., Ramon, D.,
 Tortajada, M., and Martorell, P. (2022). Lipoteichoic acid from Bifidobacterium animalis
 subsp. lactis BPL1: a novel postbiotic that reduces fat deposition via IGF-1 pathway. *Microb Biotechnol* 15, 805-816.
- Balogun, O.O., Dagvadorj, A., Anigo, K.M., Ota, E., and Sasaki, S. (2015). Factors influencing
 breastfeeding exclusivity during the first 6 months of life in developing countries: a
 quantitative and qualitative systematic review. *Maternal & child nutrition* 11, 433-451.
- Black, R.E., Victora, C.G., Walker, S.P., Bhutta, Z.A., Christian, P., De Onis, M., Ezzati, M.,
 Grantham-Mcgregor, S., Katz, J., and Martorell, R. (2013). Maternal and child undernutrition
 and overweight in low-income and middle-income countries. *The lancet* 382, 427-451.
- Boirie, Y., Dangin, M., Gachon, P., Vasson, M.P., Maubois, J.L., and Beaufrère, B. (1997). Slow and
 fast dietary proteins differently modulate postprandial protein accretion. *Proc Natl Acad Sci USA* 94, 14930-14935.
- Bosheva, M., Tokodi, I., Krasnow, A., Pedersen, H.K., Lukjancenko, O., Eklund, A.C., Grathwohl,
 D., Sprenger, N., Berger, B., Cercamondi, C.I., H.S.I.C., Bauer, V., Arciszewska, M.,
 Tarneva, M., Popova, I., Dosev, S., Dimitrova, S., Nikolova, O., Nowak, M., Szuflinska-
- 658 Sidorowicz, M., Korczowski, B., Karcheva-Beloeva, R., Banov, S., Cimoszko, B.,
- 659 Olechowski, W., Simko, R., Tengelyi, Z., Korbal, P., Zolnowska, M., Bilev, A.,
- 660 Vasilopoulos, G., Korzynska, S., Laki, I., Koleva-Syarova, M., Grigorov, T., Kraeva, S.,
- 661 Kovács, É., Markova, R., Jasieniak-Pinis, G., Fister, K., and Stoeva, T. (2022). Infant
- Formula With a Specific Blend of Five Human Milk Oligosaccharides Drives the Gut
- 663 Microbiota Development and Improves Gut Maturation Markers: A Randomized Controlled 664 Trial. *Frontiers in Nutrition* 9.

665 666 667 668 669	 Braegger, C., Chmielewska, A., Decsi, T., Kolacek, S., Mihatsch, W., Moreno, L., Piescik, M., Puntis, J., Shamir, R., Szajewska, H., Turck, D., Van Goudoever, J., and Nutrition, E.C.O. (2011). Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. <i>J Pediatr Gastroenterol Nutr</i> 52, 238-250.
670 671	Brands, B., Demmelmair, H., Koletzko, B., and Project, E. (2014). How growth due to infant nutrition influences obesity and later disease risk. <i>Acta paediatrica</i> 103, 578-585.
672 673 674 675	Campoy, C., Am, C.T., De La Garza Puentes, A., Sáenz De Pipaón, M., Verduci, E., Koletzko, B., Casanova, G., Larqué, E., Valenzuela, R., and Jm, M.V. (2021). Controversy about the critical role of long-chain polyunsaturated fatty acids, arachidonic acid (ARA) and docosahexaenoic acid (DHA), during infancy. <i>Nutricion Hospitalaria</i> .
676 677 678	Carreras, N.L., Martorell, P., Chenoll, E., Genoves, S., Ramon, D., and Aleixandre, A. (2018). Anti- obesity properties of the strain Bifidobacterium animalis subsp. lactis CECT 8145 in Zucker fatty rats. <i>Benef Microbes</i> 9, 629-641.
679 680	Carver, J.D. (2003). Advances in nutritional modifications of infant formulas. <i>The American journal of clinical nutrition</i> 77, 1550S-1554S.
681 682	Christian, P., Smith, E.R., Lee, S.E., Vargas, A.J., Bremer, A.A., and Raiten, D.J. (2021). The need to study human milk as a biological system. <i>Am J Clin Nutr</i> 113, 1063-1072.
683 684 685 686 687 688	Codex Alimentaris (2020). STANDARD FOR INFANT FORMULA AND FORMULAS FOR SPECIAL MEDICAL PURPOSES INTENDED FOR INFANTS. Formerly CAC/RS 72-1972. Adopted as a worldwide Standard in 1981. Amended in 1983, 1985, 1987, 2011, 2015, 2016, 2020. Revised in 2007. [Online]. Available: https://www.fao.org/fao-who- codexalimentarius/sh- proxy/es/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex
689 690 691 692 693	 <u>%252FStandards%252FCXS%2B72-1981%252FCXS_072e.pdf</u> [Accessed 2022-06-12]. Crawford, M.A., Wang, Y., Forsyth, S., and Brenna, J.T. (2015). The European Food Safety Authority recommendation for polyunsaturated fatty acid composition of infant formula overrules breast milk, puts infants at risk, and should be revised. <i>Prostaglandins Leukot</i> <i>Essent Fatty Acids</i> 102-103, 1-3.
694 695 696	Davis, A.M., Harris, B.J., Lien, E.L., Pramuk, K., and Trabulsi, J. (2008). Alpha-lactalbumin-rich infant formula fed to healthy term infants in a multicenter study: plasma essential amino acids and gastrointestinal tolerance. <i>Eur J Clin Nutr</i> 62, 1294-1301.
697 698	Efsa Panel on Dietetic Products, N., and Allergies (2014). Scientific Opinion on the essential composition of infant and follow on formulae. <i>EFSA Journal</i> 12, 3760.
699 700 701 702 703	Eu Commission (2016). Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the European Parliament and of the Council as regards the specific compositional and information requirements for infant formula and follow-on formula and as regards requirements on information relating to infant and young child feeding. <i>OJEC</i> 59, 1-29.
704 705 706	Flaherman, V.J., Narayan, N.R., Hartigan-O'connor, D., Cabana, M.D., Mcculloch, C.E., and Paul, I.M. (2018). The effect of early limited formula on breastfeeding, readmission, and intestinal microbiota: a randomized clinical trial. <i>The Journal of pediatrics</i> 196, 84-90. e81.

707 708 709 710	Food and Drug Administration, F. (2018). <i>Infant formula requirements pertaining to current good</i> <i>manufacturing practice, quality control procedures, quality factors, records and reports and</i> <i>notifications.</i> [Online]. Available: <u>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=106</u>
711	[Accessed 2022-06-12].
712 713	Forsyth, S., Gautier, S., and Salem, N. (2017). The importance of dietary DHA and ARA in early life: a public health perspective. <i>Proc Nutr Soc</i> 76, 568-573.
714 715	Gopalakrishna, K.P., and Hand, T.W. (2020). Influence of Maternal Milk on the Neonatal Intestinal Microbiome. <i>Nutrients</i> 12.
716 717	Horta, B.L., Loret De Mola, C., and Victora, C.G. (2015). Breastfeeding and intelligence: a systematic review and meta-analysis. <i>Acta Paediatr</i> 104, 14-19.
718 719 720	Ip, S., Chung, M., Raman, G., Trikalinos, T.A., and Lau, J. (2009). A summary of the Agency for Healthcare Research and Quality's evidence report on breastfeeding in developed countries. <i>Breastfeed Med</i> 4 Suppl 1, S17-30.
721 722 723	Jackson, J.G., Janszen, D.B., Lonnerdal, B., Lien, E.L., Pramuk, K.P., and Kuhlman, C.F. (2004). A multinational study of alpha-lactalbumin concentrations in human milk. <i>J Nutr Biochem</i> 15, 517-521.
724 725	Jasani, B., Simmer, K., Patole, S.K., and Rao, S.C. (2017). Long chain polyunsaturated fatty acid supplementation in infants born at term. <i>Cochrane Database Syst Rev</i> 3, Cd000376.
726 727 728 729	Kim, J.Y., Kwon, J.H., Ahn, S.H., Lee, S.I., Han, Y.S., Choi, Y.O., Lee, S.Y., Ahn, K.M., and Ji, G.E. (2010). Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. <i>Pediatr Allergy Immunol</i> 21, e386-393.
730 731 732 733 734	 Koletzko, B., Baker, S., Cleghorn, G., Neto, U.F., Gopalan, S., Hernell, O., Hock, Q.S., Jirapinyo, P., Lonnerdal, B., Pencharz, P., Pzyrembel, H., Ramirez-Mayans, J., Shamir, R., Turck, D., Yamashiro, Y., and Zong-Yi, D. (2005). Global standard for the composition of infant formula: recommendations of an ESPGHAN coordinated international expert group. <i>J Pediatr Gastroenterol Nutr</i> 41, 584-599.
735 736 737 738	Koletzko, B., Bergmann, K., Brenna, J.T., Calder, P.C., Campoy, C., Clandinin, M.T., Colombo, J., Daly, M., Decsi, T., and Demmelmair, H. (2020). Should formula for infants provide arachidonic acid along with DHA? A position paper of the European Academy of Paediatrics and the Child Health Foundation. <i>The American journal of clinical nutrition</i> 111, 10-16.
739 740 741 742 743	 Koletzko, B., Von Kries, R., Closa, R., Escribano, J., Scaglioni, S., Giovannini, M., Beyer, J., Demmelmair, H., Gruszfeld, D., Dobrzanska, A., Sengier, A., Langhendries, JP., Rolland Cachera, MF., Grote, V., and European Childhood Obesity Trial Study Group (2009). Lower protein in infant formula is associated with lower weight up to age 2 y: a randomized clinical trial. <i>The American journal of clinical nutrition</i> 89, 1836-1845.
744 745 746 747 748	 Kouwenhoven, S.M.P., Antl, N., Finken, M.J.J., Twisk, J.W.R., Van Der Beek, E.M., Abrahamse-Berkeveld, M., Van De Heijning, B.J.M., Van Goudoever, J.B., and Koletzko, B.V. (2021). Long-term effects of a modified, low-protein infant formula on growth and body composition: Follow-up of a randomized, double-blind, equivalence trial. <i>Clin Nutr</i> 40, 3914-3921.

749 Kramer, M., and Kakuma, R. (2001). "The optimal duration of exclusive breastfeeding: a systematic rewiew. Geneva: World Halth Organization, 2001. 47 p". WHO/NHD/01.08). 750 751 Li, L., Han, Z., Niu, X., Zhang, G., Jia, Y., Zhang, S., and He, C. (2019). Probiotic Supplementation 752 for Prevention of Atopic Dermatitis in Infants and Children: A Systematic Review and Meta-753 analysis. Am J Clin Dermatol 20, 367-377. 754 Liao, Y., Weber, D., Xu, W., Durbin-Johnson, B.P., Phinney, B.S., and Lönnerdal, B. (2017). 755 Absolute Quantification of Human Milk Caseins and the Whey/Casein Ratio during the First 756 Year of Lactation. J Proteome Res 16, 4113-4121. 757 Lien, E.L., Richard, C., and Hoffman, D.R. (2018). DHA and ARA addition to infant formula: 758 Current status and future research directions. Prostaglandins Leukot Essent Fatty Acids 128, 759 26-40. 760 Lönnerdal, B., and Lien, E.L. (2003). Nutritional and physiologic significance of alpha-lactalbumin 761 in infants. Nutr Rev 61, 295-305. 762 Meddra, M. (2018). "Introductory Guide for Standardised MedDRA Queries (SMQs) Version 763 21.0".). 764 Monasta, L., Batty, G., Macaluso, A., Ronfani, L., Lutje, V., Bavcar, A., Van Lenthe, F., Brug, J., 765 and Cattaneo, A. (2011). Interventions for the prevention of overweight and obesity in 766 preschool children: a systematic review of randomized controlled trials. Obesity reviews 12, 767 e107-e118. 768 Nataraj, B.H., Ali, S.A., Behare, P.V., and Yadav, H. (2020). Postbiotics-parabiotics: the new 769 horizons in microbial biotherapy and functional foods. Microb Cell Fact 19, 168. Ogbu, C.E., Fongue, S., Ogbu, S.C., and Kirby, R.S. (2021). Infant feeding practices and asthma in 770 771 children aged 6 months to 5 years using a propensity score approach. Cent Eur J Public 772 Health 29, 284-289. 773 Pedret, A., Valls, R.M., Calderon-Perez, L., Llaurado, E., Companys, J., Pla-Paga, L., Moragas, A., 774 Martin-Lujan, F., Ortega, Y., Giralt, M., Caimari, A., Chenoll, E., Genoves, S., Martorell, P., 775 Codoner, F.M., Ramon, D., Arola, L., and Sola, R. (2019). Effects of daily consumption of 776 the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity 777 biomarkers in abdominally obese subjects: a randomized controlled trial. Int J Obes (Lond) 778 43.1863-1868. 779 Poth, A.G., Deeth, H.C., Alewood, P.F., and Holland, J.W. (2008). Analysis of the human casein 780 phosphoproteome by 2-D electrophoresis and MALDI-TOF/TOF MS reveals new 781 phosphoforms. J Proteome Res 7, 5017-5027. 782 Räihä, N.C., Fazzolari-Nesci, A., Cajozzo, C., Puccio, G., Monestier, A., Moro, G., Minoli, I., 783 Haschke-Becher, E., Bachmann, C., Van't Hof, M., Carrié Fässler, A.L., and Haschke, F. 784 (2002). Whey predominant, whey modified infant formula with protein/energy ratio of 1.8 785 g/100 kcal: adequate and safe for term infants from birth to four months. J Pediatr 786 Gastroenterol Nutr 35, 275-281. 787 Rameez, R.M., Sadana, D., Kaur, S., Ahmed, T., Patel, J., Khan, M.S., Misbah, S., Simonson, M.T., 788 Riaz, H., and Ahmed, H.M. (2019). Association of Maternal Lactation With Diabetes and 789 Hypertension: A Systematic Review and Meta-analysis. JAMA Netw Open 2, e1913401.

- Ren, Q., Li, K., Sun, H., Zheng, C., Zhou, Y., Lyu, Y., Ye, W., Shi, H., Zhang, W., Xu, Y., and
 Jiang, S. (2022). The Association of Formula Protein Content and Growth in Early Infancy: A
 Systematic Review and Meta-Analysis. *Nutrients* 14.
- Ruiz-Ojeda, F.J., Plaza-Diaz, J., Morales, J., De La Torre, A.I.C., Garcia-Garcia, A., De Prado, C.N.,
 Coronel, C., Crespo, C., Ortega, E., and Martin-Perez, E. (2022). A multicenter, randomized,
 blinded, controlled clinical trial investigating the effect of a novel infant formula on the body
 composition of infants: INNOVA 2020 study protocol. *medRxiv*.
- Salminen, S., Collado, M.C., Endo, A., Hill, C., Lebeer, S., Quigley, E.M.M., Sanders, M.E., Shamir,
 R., Swann, J.R., Szajewska, H., and Vinderola, G. (2021). The International Scientific
 Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and
 scope of postbiotics. *Nat Rev Gastroenterol Hepatol* 18, 649-667.
- Sandström, O., Lönnerdal, B., Graverholt, G., and Hernell, O. (2008). Effects of alpha-lactalbumin enriched formula containing different concentrations of glycomacropeptide on infant
 nutrition. *Am J Clin Nutr* 87, 921-928.
- Silva, A., Gonzalez, N., Terren, A., Garcia, A., Martinez-Blanch, J.F., Illescas, V., Morales, J.,
 Maroto, M., Genoves, S., Ramon, D., Martorell, P., and Chenoll, E. (2020). An Infant Milk
 Formula Supplemented with Heat-Treated Probiotic Bifidobacterium animalis subsp. lactis
 CECT 8145, Reduces Fat Deposition in C. elegans and Augments Acetate and Lactate in a
 Fermented Infant Slurry. *Foods* 9.
- Szajewska, H., Canani, R.B., Guarino, A., Hojsak, I., Indrio, F., Kolacek, S., Orel, R., Shamir, R.,
 Vandenplas, Y., Van Goudoever, J.B., Weizman, Z., and Probioticsprebiotics, E.W.G.F.
 (2016). Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. *J Pediatr Gastroenterol Nutr* 62, 495-506.
- Task Force on Clinical Testing of Infant Formulas Committee on Nutrition. American Academy of
 Pediatrics Committee on Nutrition, L, F., Bell Ef, Cooke Rj, Fomon Sj, Kleinman Re,
 Pencharz Pb, Reynolds Jw, Schanler Rj, and Al, F. (1988). *Clinical Testing of Infant Formulas With Respect to Nutritional Suitability for Term Infants* [Online]. Available:
 https://wayback.archive-
- 818it.org/7993/20170722090324/https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocu819mentsRegulatoryInformation/InfantFormula/ucm170649.htm [Accessed 2022-06-24].
- Thomas, D.W., Greer, F.R., American Academy of Pediatrics Committee On, N., American
 Academy of Pediatrics Section on Gastroenterology, H., and Nutrition (2010). Probiotics and
 prebiotics in pediatrics. *Pediatrics* 126, 1217-1231.
- Timby, N., Domellöf, E., Hernell, O., Lönnerdal, B., and Domellöf, M. (2014). Neurodevelopment,
 nutrition, and growth until 12 mo of age in infants fed a low-energy, low-protein formula
 supplemented with bovine milk fat globule membranes: a randomized controlled trial. *Am J Clin Nutr* 99, 860-868.
- Totzauer, M., Luque, V., Escribano, J., Closa-Monasterolo, R., Verduci, E., Redionigi, A., Hoyos, J.,
 Langhendries, J.P., Gruszfeld, D., Socha, P., Koletzko, B., Grote, V., and European
 Childhood Obesity Trial Study, G. (2018). Effect of Lower Versus Higher Protein Content in
 Infant Formula Through the First Year on Body Composition from 1 to 6 Years: Follow-Up
 of a Randomized Clinical Trial. *Obesity (Silver Spring)* 26, 1203-1210.

Vesa, S., Kleemola, M., Blomqvist, S., Takala, A., Kilpi, T., and Hovi, T. (2001). Epidemiology of 832 833 documented viral respiratory infections and acute otitis media in a cohort of children followed 834 from two to twenty-four months of age. Pediatr Infect Dis J 20, 574-581. 835 Victora, C.G., Bahl, R., Barros, A.J., França, G.V., Horton, S., Krasevec, J., Murch, S., Sankar, M.J., 836 Walker, N., and Rollins, N.C. (2016). Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. The lancet 387, 475-490. 837 838 Victora, C.G., Horta, B.L., Loret De Mola, C., Quevedo, L., Pinheiro, R.T., Gigante, D.P., 839 Gonçalves, H., and Barros, F.C. (2015). Association between breastfeeding and intelligence, 840 educational attainment, and income at 30 years of age: a prospective birth cohort study from 841 Brazil. Lancet Glob Health 3, e199-205. 842 Vinderola, G., Sanders, M.E., and Salminen, S. (2022). The Concept of Postbiotics. Foods 11. 843 Walker, A. (2010). Breast milk as the gold standard for protective nutrients. J Pediatr 156, S3-7. 844 Wallingford, J.C., and Barber, C. (2019). A review of studies on the growth of infants fed infant 845 formula. Current Developments in Nutrition 3, nzz095. 846 Weber, M., Grote, V., Closa-Monasterolo, R., Escribano, J., Langhendries, J.P., Dain, E., Giovannini, 847 M., Verduci, E., Gruszfeld, D., Socha, P., and Koletzko, B. (2014a). Lower protein content in 848 infant formula reduces BMI and obesity risk at school age: follow-up of a randomized trial. 849 Am J Clin Nutr 99, 1041-1051. 850 World Health Organization (2002). The optimal duration of exclusive breastfeeding: a systematic 851 review [Online]. Available: 852 https://apps.who.int/iris/bitstream/handle/10665/67208/WHO_NHD_01.08.pdf [Accessed]. 853 World Health Organization (2022). World Health Organization breastfeeding recommendations 854 [Online]. Available: https://www.who.int/health-topics/breastfeeding/ [Accessed 2022-06-12]. 855 Zheng, M., Lamb, K.E., Grimes, C., Laws, R., Bolton, K., Ong, K.K., and Campbell, K. (2018). 856 857 Rapid weight gain during infancy and subsequent adiposity: A systematic review and 858 meta analysis of evidence. *Obesity Reviews* 19, 321-332. 859 Ziegler, E.E. (2006). Growth of breast-fed and formula-fed infants. Nestle Nutr Workshop Ser 860 Pediatr Program 58, 51-59; discussion 59-63.

861











С













в